What is the appropriate evaluation and management for a patient on anti‑tubercular therapy who develops new‑onset slurred speech?

Evaluation and Management of Slurred Speech in a Patient on Anti-Tubercular Therapy

Stop all anti-tubercular drugs immediately and evaluate for drug-induced central nervous system toxicity, particularly isoniazid-induced peripheral neuropathy affecting cranial nerves, ethambutol optic/neurologic toxicity, or a paradoxical CNS tuberculoma as part of immune reconstitution inflammatory syndrome (IRIS).

Immediate Actions

Discontinue Anti-Tubercular Therapy

• Stop all anti-TB drugs immediately until the etiology of slurred speech is determined, as this represents a potentially serious neurologic adverse event that requires urgent evaluation 1.
• Slurred speech (dysarthria) may indicate CNS involvement, cranial nerve dysfunction, or drug toxicity—all of which require immediate assessment before continuing therapy 2.

Emergency Neurologic Evaluation

• Perform urgent neuroimaging (MRI brain with contrast) to evaluate for:
  • New or enlarging CNS tuberculomas (paradoxical IRIS reaction) 3, 2
  • Tuberculous meningitis (if not previously diagnosed) 2
  • Other intracranial pathology including stroke or mass effect 2
• Complete neurologic examination focusing on:
  • Cranial nerve function (particularly III, VII, IX, X, XII which affect speech and swallowing) 3
  • Motor and sensory deficits 2
  • Signs of meningeal irritation (neck stiffness, photophobia) 2
  • Visual acuity and visual fields (ethambutol toxicity) 1

Differential Diagnosis and Specific Evaluations

Drug-Induced Toxicity

• Isoniazid peripheral neuropathy: Check for concurrent peripheral neuropathy symptoms (paresthesias, weakness); measure serum B6 levels if available 1.
• Ethambutol neurotoxicity: Perform formal visual acuity testing and visual field assessment, as ethambutol can cause optic neuropathy and rarely other neurologic effects 1.
• Rifampicin interactions: Review all concurrent medications for potential drug interactions that may cause CNS effects 1.

Paradoxical CNS Tuberculoma (IRIS)

• New tuberculoma formation can occur even after 9 months of appropriate therapy and presents with new neurologic deficits including cranial nerve palsies and speech disturbances 3.
• MRI findings of new or enlarging tuberculomas in a patient with clinical worsening despite adequate treatment duration strongly suggest IRIS 3, 2.
• This phenomenon does not represent treatment failure but rather an exaggerated immune response 3.

CNS Tuberculosis Progression

• Lumbar puncture with CSF analysis if meningitis is suspected (and no contraindications exist):
  • CSF cell count with differential (expect lymphocytic pleocytosis) 2
  • CSF protein (typically elevated >1 g/L) 2
  • CSF glucose with simultaneous plasma glucose (CSF:plasma ratio <50% suggests TB meningitis) 2
  • CSF mycobacterial culture and molecular testing 2

Management Based on Etiology

If Drug Toxicity is Confirmed

• Do not reintroduce the offending drug if severe neurotoxicity (e.g., ethambutol optic neuropathy, severe isoniazid neuropathy) is confirmed 1.
• Substitute alternative agents: Use streptomycin (if not contraindicated) or a fluoroquinolone to complete the regimen 1.
• Add pyridoxine 50-100 mg daily if isoniazid-induced neuropathy is suspected, even if not previously prescribed 1.
• Extend treatment duration to 9-12 months if rifampicin or pyrazinamide must be omitted 1.

If Paradoxical CNS Tuberculoma (IRIS) is Diagnosed

• Continue anti-tubercular therapy without modification—do not stop or change the regimen 3, 2.
• Initiate corticosteroids immediately: Dexamethasone or prednisolone should be given to all patients with CNS tuberculosis complications 2.
  • Typical dosing: Dexamethasone 0.3-0.4 mg/kg/day or prednisolone 1-2 mg/kg/day, with gradual taper over 6-8 weeks 2.
• Avoid surgical intervention for paradoxical enlargement, as this represents an inflammatory process that responds to steroids, not treatment failure 3, 2.
• Extend total treatment duration to at least 12 months for any form of CNS tuberculosis 2, 4.

If New or Progressive CNS Tuberculosis

• Restart four-drug therapy (isoniazid, rifampicin, pyrazinamide, ethambutol) immediately if CNS TB is confirmed and drugs were stopped 2.
• Add adjunctive corticosteroids (dexamethasone or prednisolone) regardless of disease severity 2.
• Treat for minimum 12 months total duration (2 months intensive phase with 4 drugs, followed by 10 months continuation phase with isoniazid and rifampicin) 2, 4.

Critical Monitoring and Follow-Up

Ongoing Surveillance

• Weekly clinical neurologic assessments until symptoms stabilize or improve 2.
• Repeat MRI at 4-6 weeks to assess response to therapy and distinguish treatment failure from paradoxical reaction 3, 2.
• Monthly visual acuity checks if ethambutol is continued 1.

HIV Considerations

• Test for HIV infection if not previously done, as HIV-positive patients have higher rates of CNS tuberculosis, paradoxical reactions, and drug toxicity 1, 2.
• Delay antiretroviral therapy (ART) initiation by 8 weeks in patients with CNS tuberculosis to reduce risk of severe IRIS, unless CD4 count is <50 cells/μL 1.

Common Pitfalls to Avoid

• Do not dismiss new neurologic symptoms as "expected" during TB treatment—they always warrant urgent evaluation 2.
• Do not mistake paradoxical enlargement of tuberculomas for treatment failure—continue therapy and add steroids rather than changing the regimen 3, 2.
• Do not restart ethambutol if optic neurotoxicity is confirmed—permanent vision loss can result 1.
• Do not use shorter 6-month regimens for CNS tuberculosis—minimum 12 months is required 2, 4.
• Do not perform lumbar puncture if imaging shows mass effect or elevated intracranial pressure—risk of herniation 2.